Artiva Biotherapeutics, Inc. (ARTV)
(Delayed Data from NSDQ)
$2.76 USD
+0.12 (4.55%)
Updated Aug 8, 2025 03:59 PM ET
After-Market: $2.76 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARTV 2.76 +0.12(4.55%)
Will ARTV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARTV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARTV
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
ARTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARTV
Artiva Biotherapeutics GAAP EPS of -$0.87 misses by $0.06
Artiva Biotherapeutics files $300M mixed securities shelf
12 Health Care Stocks Moving In Wednesday's After-Market Session
Artiva Biotherapeutics Approves Equity Plan Amendment
Promising Advancements and Financial Strength Position Artiva Biotherapeutics for Significant Upside